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Abstract
Cervical dystonia (CD) is the most common focal dystonia that is characterized by
involuntary contraction of cervical muscles causing abnormal head movements and
postures. The treatment for CD was previously limited to oral medications, however,
with consequent systemic side effects. In recent years, botulinum toxin (BoNT) has
demonstrated efficacy in several studies and thus has received level A recommendation
from both  the  American Academy of  Neurology and the  European Federation  of
Neurological Sciences in the treatment of dystonia. In many countries, it is the first‐line
treatment for CD. There are four types of toxin approved for the use in CD, three type
A  [OnabotulinumtoxinA  (OnaBoNTA),  AbobotulinumtoxinA  (AboBoNTA),  and
Incobotulinumtoxin A (IncoBoNTA)] and one type B [RimabotulinumtoxinB (Rima‐
BoNTB)].  Proper  selection  of  affected  muscles  and  dose  of  toxin  are  important
parameters in successfully providing symptomatic treatment. Good response rate is
defined as improvement of more than 25 % from baseline using the Toronto Western
Torticollis Rating Scale. The most common side effect of chemodenervation with BoNT
for CD is dysphagia.
Keywords: cervical dystonia, OnaBoNTA, AboBoNTA, IncoBoNTA, RimaBoNTB, bot‐
ulinum toxin
1. Introduction
Cervical dystonia (CD) is a movement disorder characterized by involuntary contractions of
cervical muscles causing abnormal head movements and postures, at times associated with
head tremor and chronic pain [1,  2].  The prevalence of  CD in the general  population is
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estimated to vary from 0.006% from a clinic‐based study in eight European countries to 0.4%
in the USA, based on a consumer database survey [3, 4].
CD remains the most common of the focal dystonias [3, 5]. Classifications of CD include
torticollis (turning or rotation of the head towards one side); laterocollis (tilting of the head
towards one side); anterocollis (head and neck flexion); and retrocollis (head and neck
extension) or a combination of these movements [1, 2]. The peak age of onset is around 41.8 
years, although it can occur in all ages and is slightly more common in females [6]. Most cases
of CD are idiopathic, and there is a family history in about 12% of cases [2]. It can also be
secondary to trauma or musculoskeletal, spinal cord, intracranial, ocular, and vestibular
disorders [7].
For objective rating of CD, the clinician has to use dedicated scales. Scoring at baseline, at the
time of peak effect (approximately 1 month after injection) and before retreatment would allow
the injectors to assess the outcome of the previous injection and make the necessary adjustment
in the dosing and targeting in the next injection cycle [8]. The most frequently used instrument
to assess the response to therapeutic interventions in patients with CD is the Toronto Western
Spasmodic Torticollis Rating Scale (TWSTRS) [9]. The TWSTRS, together with the Cervical
Dystonia Impact Scale (CDIP‐58) and the Cervical Dystonia Questionnaire (CDQ‐24), is
“recommended” for CD, while the Functional Disability Questionnaire, the Tsui Scale and the
Body Concept Scale have been rated as “suggested” [10].
2. Muscle selection
Upon diagnosis of CD, a proper clinical examination is warranted. One has to identify the
primary muscles involved as opposed to compensatory activity as well as dose selection by
the injector [8, 11].
The proper identification of muscles involved in CD cannot be overemphasized and requires
an understanding of the different actions of the neck muscles. When examining the patient,
dystonic muscles are best assessed when the neck is at rest or in submaximal contraction [8,
12]. More often than not, the dystonic muscles will show hypertrophy and are quite prominent.
Superficial muscles are easily identified and palpated, making it easier to identify and inject.
However, with deeper muscles, co‐contraction of superficial muscles, or in certain cases where
there is relative small muscle bulk, identification can be difficult.
Isolated postural deviations of the head occur in less than one‐third of patients, while complex
deviations occur in 66–80% of patients [1, 2]. There are generally four planes of movement in
CD. However, most cases are compounded involving a combination of at least two movements,
making muscle and dose selection more difficult.
Torticollis is when the neck turns from left to right or right to left along the horizontal axis in
the coronal plane [22] (Figure 1A). Effector muscles for this action include the contralateral
sternocleidomastoid and the ipsilateral splenius capitis, as well as other supporting neck
muscles. In latercollis, the head tilts to one side along the vertical plane (Figure 1B). The
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movement is facilitated by the contractions of the ipsilateral splenius, sternocleidomastoid,
scalene complex, levator scapulae, and posterior paravertebral muscles. In anterocollis, the
head tilts forward (Figure 1C) and there is contraction of both sternocleidomastoids, scalene
complex and the submental complex. Retrocollis is the opposite of the anterocollis, where the
head tilts backwards (Figure 1D) and there are bilateral contractions of the splenius, deep
paravertebral muscles, and upper trapezius. When compounded movements are present,
muscle selection becomes more tedious and varying doses may prove beneficial. This includes
identifying the more active dystonic muscles and preferentially giving these muscles a higher
dose. In a patient who presents with both retrocollis and left torticollis (Figure 1E), the
contralateral sternocleidomastoid and both splenius capitis muscles are chemodenervated,
with the ipsilateral splenius receiving a higher dose than the contralateral counterpart. Another
compound movement involves the lateral displacement of the neck along the horizontal axis
(Figure 1F). A summary of involved muscles in the four general planes and some compound
movements is seen in Table 1.
Figure 1. Different types of cervical dystonia. (A) Left torticollis, where the neck rotates to the left along the horizontal
axis; (B) left laterocollis with the neck turned to the left along the vertical axis; (C) antecollis with the neck bent for‐
ward; (D) retrocollis with the neck bent backwards; (E) compound movement of both torticollis and retrocollis to the
left with left shoulder elevation; and (F) lateral displacement of the neck along the horizontal axis.












CL SCM  20–50  40–120  20–50  1000–3000 
CL Anterior scalene  5–30  20–100  5–30  500–2000 
CL Middle scalene  5–30  20–100  5–30  500–2000 
CL Semispinalis
capitis 
20–100  60–250  20–100  1000–2000 
CL Levator scapulae  20–100  60–200  20–100  1000–2000 
IP Splenius capitis  40–100  100–350  40–100  1000–4000 
IP Longus capitis  15–30  20–60  15–30  ND 
Laterocollis 
IP SCM  20–50  40–120  20–50  1000–3000 
IP Anterior scalene  5–30  20–100  5–30  500–2000 
IP Middle scalene  5–30  20–100  5–30  500–2000 
IP Posterior scalene  5–30  20–100  5–30  500–2000 
IP Splenius capitis  40–100  100–350  40–100  1000–4000 
IP Semispinalis capitis  20–100  60–250  20–100  1000–2000 
IP Levator scapulae  20–100  60–250  20–100  1000–2000 
IP Trapezius  25–100  60–300  25–100  1000–4000 
Retrocollis 
IP Splenius capitis  40–100  100–350  40–100  1000–4000 
CL Splenius capitis  40–100  100–350  40–100  1000–4000 
IP Semispinalis capitis  20–100  60–250  20–100  1000–2000 
CL Semispinalis
capitis 
20–100  60–250  20–100  1000–2000 
IP Trapezius  25–100  60–300  25–100  1000–4000 
CL Trapezius  25–100  60–300  25–100  1000–4000 
Anterocollis 
IP SCM  20–50  40–120  20–50  1000–3000 
CL SCM  20–50  40–120  20–50  1000–3000 
IP Longus collis  15–30  20–60  15–30  ND 
CL Longus collis  15–30  20–60  15–30  ND 
IP Anterior scalene  5–30  20–100  5–30  500–2000 
CL Anterior scalene  5–30  20–100  5–30  500–2000 
IP: ipsilateral; CL: contralateral; ND: No Data; SCM: sternocleidomastoid.
Table 1. Target muscles and dose of BoNT for CD.
The use of equipment such as electromyography (EMG), ultrasonography, endoscopic/
fluoroscopic, and even computed tomography guidance may help to locate the target muscles
and thus lessen occurrence of unintended weakness of uninjected muscles [8, 13–16]. This is
discussed in another chapter.
Botulinum Toxin Therapy Manual for Dystonia and Spasticity68
3. Treatment of cervical dystonia
The treatment of CD was initially limited to oral medication and eventually surgery.
These medications include anticholinergics, benzodiazepines, and antispasticity medications
[17]. As much as 40% of patients reported improvement with trihexyphenidyl [18, 19].
However, these medications are often of limited benefit due to systemic side effects. Surgery
with deep brain stimulation or selective peripheral denervation surgery for CD has shown
inconsistent results [20–23].
The efficacy of Botulinum toxin (BoNT) has been demonstrated, warranting both European
Federation of Neurological Societies (EFNS) and the American Association of Neurology
(AAN) level A recommendations as first‐line treatment [24, 25]. BoNT has been approved for
use in many countries and remains the treatment of choice for CD [8, 18, 26, 27]. Recent studies
also provided level A evidence supporting for the treatment of CD [28].
In its updated guideline, the AAN has now differentiated the different serotypes/preparations
of BoNT and its level of evidence for CD: AboBoNTA and RimaBoNTB should be offered (Level
A) while OnaBoNTA and IncoBoNTA should be considered (Level B), as options for the
treatment of CD [26].
Reviews of BoNT treatment for CD suggest that 70–90% of patients derive symptomatic benefit
from BoNT with at least one injection [29–31]. In a meta‐analysis (8 trials with 361 patients
using OnaBoNTA; 5 trials with 319 patients using AboBoNTA), it was shown that there was a
statistically and clinically significant improvement on objective rating scales and subjective
rating scales as well as for pain relief in subjective scales [7]. The same was also seen in a real‐
world design study (1046 patients) showing robust improvement in clinical ratings as meas‐
ured via both physician‐ and subject‐reported outcomes and excellent tolerability following
OnaBoNTA treatment of CD [30].
There is no consensus on the duration of effect of the various BoNT in the treatment of CD.
The minimum treatment duration was 7.8 ± 1.4 weeks, and maximum treatment duration was
21.0 ± 3.9 weeks [32]. Only 49.3% of patients rated the duration of response of >12 weeks for all
BoNTA preparations [33]. In a comparative study of BoNT preparations for the treatment of
CD, a significant difference in overall duration of effect was seen between the various groups
with a mean duration of 104.3 days for the current formulation of OnaBoNTA, 75.7 days for
AboBoNTA, and 91.2 days for RimaBoNTB [34].
OnaBoNTA and IncoBoNTA have comparable efficacies with a 1:1 conversion ratio and have
demonstrated therapeutic equivalence in different indications including CD. An OnaBoNTA
to AboBoNTA conversion ratio of 1:3, or even less, should be considered the most appropriate
[35–38]. It is interesting that an Asian study found a clinical equivalent ratio of 1:2.5 [39]. A
robust conversion factor of estimating the equivalent doses of BoNTA and Botulinum toxin B
(BoNTB) remains to be tested in the clinics.
The injection interval of BoNT for the treatment of CD is typically 3–4 months in most clinical
practices [40]. In one study (59 subjects), the inter‐injection interval was 15.4 ± 3.4 weeks [32].
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In the CD‐PROBE registry, the mean time between treatments increased from 14.6 ± 4.1 weeks
following treatment session 1 to 15.1 ± 5.2 weeks after treatment session 2 [30].
A single injection cycle of BoNT is effective and safe for treating CD, and further injection
cycles continue to work for most patients [7].
4. Botulinum toxin therapy dosing
The appropriate dose given to the target muscles is equally important in a successful injection
session. There are several types of BoNTs available; however, only four types have been
approved for use in CD: three type A and one type B toxin. The approved toxins for use are
OnaBoNTA (Botox), AboBoNTA (Dysport), IncoBoNTA (Xeomin), and RimaBoNTB (Neuro‐
Bloc/Myobloc). Although three of these are type A toxins, they are not equivalent. A summary
of the common muscles to be injected according to the type of CD and its BoNT doses is
presented in Table 1. Generally, in the initial treatment session, each muscle injected should
not exceed 200 units for OnaBoNTA and IncoBoNTA, 500 units for AboBoNTA, and 5000 units
for RimaBoNTB. The total dose given per patient per session should also not exceed 400 units
for OnaBoNTA and IncoBoNTA, 1000 units for AboBoNTA, and 10,000 units for RimaBoNTB
[8, 36].
5. Challenges with BoNT therapy
Responders to BoNT therapy is based on four criteria: magnitude of effect defined as more
than 25% improvement in the TWSTRS, at least 12‐week duration of effect as reported by the
patient, tolerability defined as absence of severe related adverse events, and subjective
perception of improvement [33].
For nonresponders, the clinician has to know whether the patient is a primary or secondary
nonresponder or is a poor responder (treatment failure) [45]. Common determinants for an
unsuccessful chemodenervation session/poor responder include suboptimal doses, subopti‐
mal muscle targeting, intolerable side effects, and complex movement patterns, discordant
expectations, and an incorrect diagnosis [46].
Although BoNTA resistance is a recognized entity, secondary nonresponse maybe due to other
factors including the underlying severity of the CD [27, 47]. When confronted with these
situations, it is prudent to investigate with neuroimaging techniques before the next injection
session. A CT scan of the neck to visualize the cervical spine may help define the nature of
dystonia. Employing this imaging technique is based on the new phenomenological classifi‐
cation for CD by Reichel with reference to the position of the cervical vertebrae from the head
position. Torticollis and laterocollis involves the same angle of rotation from across all cervical
vertebrae; however, when there is torticaput or laterocaput, the base of the skull and C1 are
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on the same degree of rotation but differ from the rest of the cervical spine [48, 49]. The
challenge for the injector confronted with these movements is to target deeper and smaller
muscles. In patients with torticaput, it has been shown that 73% of cases involve the obliquus
capitis inferior [49]. It is important to keep this in mind and to discuss the planned session with
the patient including expected results to optimize treatment [8].
6. Adverse events
BoNT has a favorable safety profile. There is often a delicate balance to be found between
achieving optimal efficacy and avoiding adverse events (AEs) [50]. The AEs of BoNT treatment
are usually mild and self‐limiting and similar in both nature and severity between the different
formulations [8]. However, in some cases the outcome is disappointing or side effects occur.
This can be due to the fact that either the target muscles were not injected accurately or
unintended weakness of nontarget muscles occurred [15].
The most common AEs related to BoNT type A are as follows: dysphagia; neck muscle
weakness; injection site pain; and “flu‐like” symptoms [51]. AEs of BoNT type A are dose‐
related and mostly due to contiguous or distant spread of toxin. Therefore, it is important that
injections are located precisely so that potential spread of toxin is minimized.
A meta‐analysis of 36 randomized controlled studies reported AEs in 25% (353/1425) of the
OnaBoNTA‐treated patient versus 15% (133/884) in controls [52].
In a systematic review of the various preparations of BoNT in the treatment of CD, a signifi‐
cantly higher rate of dysphagia and positive dose‐related effect were reported with AboBoNTA
compared with the current formulation of OnaBoNTA or RimaBoNTB [34]. However, in
another study, it was mentioned that the dysphagia did not appear to be dose‐ or treatment
cycle‐related [53].
In the CD‐PROBE registry, 185 patients (17.8%) given OnaBoNTA experienced treatment‐
related adverse events. The most common events were weakness (6.9%, 185 subjects), dys‐
phagia (6.2%, 65 subjects), and neck pain (2.3%, 24 subjects) [30].
For IncoBoNTA, the most frequently reported adverse events were dysphagia, neck pain, and
muscle weakness which were usually mild [54].
Dry mouth was reported more frequently in the studies of RimaBoNTB compared to the
formulations of BoNT type A; however, a dose‐related effect was not seen with RimaBoNTB
[34].
Most of these complications resolve spontaneously, usually within 2 weeks. Dysphagia was
most frequently related to bilateral injection into sternocleidomastoid muscles [55, 56].
Measures to minimize these adverse events include always using the lowest effective dose.




BoNT remains the treatment of choice for CD. There are three BoNT type A and one BoNT
type B formulations that are currently approved, and each has its own unique pharmacologic
properties that may confer different side effect profiles, duration of therapeutic effects, and
dosing recommendations [57,58].
A number of factors need to be considered in BoNT treatment. These include the correct
diagnosis of CD, number and selection of neck and adjacent muscles to inject, the amount dose
to use, and the length of intervals of reinjection. One has to remember that each patient will
have to be individually assessed for dose and response optimization.
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